Stockreport

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Hytrulo (efgartigimod) for a second indication — chronic inflammatory demyelinating polyneuropathy (CIDP). Vyvgart Hytrulo has been approved as a once-weekly 30-to-90- [Read more]